IPAY 2026 already cut three T2D agents by 66-79%. IPAY 2027 adds semaglutide, Janumet, and Tradjenta to the same table, and each cycle changes the competitive net-price map differently.
Type 2 diabetes has more IRA-negotiated agents on the books than any other therapy area, because CMS selected agents from this class in both of its first two negotiation cycles. IPAY 2026, effective January 1 2026, set Maximum Fair Prices of $113 a month for Januvia (sitagliptin) off a $527 list, a 79% cut; $197 for Jardiance (empagliflozin) off $573, a 66% cut; and $178 for Farxiga (dapagliflozin) off $556, a 68% cut. Those three cuts alone reset the DPP-4 and SGLT2 formulary tiers that most commercial plans had built around list-minus-rebate economics.
IPAY 2027 widens the negotiated set again, and does so across drug classes rather than within one. Semaglutide's franchise (Ozempic, Rybelsus, Wegovy) is cut 71% to $274 for a 30-day supply off a roughly $959 list. Janumet (sitagliptin/metformin) and Tradjenta (linagliptin) join the negotiated list for the same cycle. A pricing strategy built only on the IPAY 2026 cohort is now incomplete; the negotiated share of the T2D formulary roughly doubles in scope from 2026 to 2027, and each new agent added changes which comparator a payer will reference when negotiating the agents CMS has not yet touched.
ICER's 2019 assessment of oral semaglutide (Rybelsus) is the value-based anchor still in use for the DPP-4/SGLT2/GLP-1 comparison, and it is not a flat verdict. ICER found oral semaglutide met cost-effectiveness thresholds as an add-on to metformin, but rated it less cost-effective than empagliflozin in the same add-on-to-metformin position. That finding predates both negotiation cycles, and the two negotiated prices now sitting below ICER's threshold (Jardiance's $197 MFP, semaglutide's $274 MFP) change how that 2019 ranking should be read for a 2026-2027 formulary decision.
US type 2 diabetes IRA negotiation — IPAY 2026 vs IPAY 2027 compared
| Agent | Negotiation Cycle | List Price (monthly) | Negotiated MFP | Discount |
|---|---|---|---|---|
| Januvia (sitagliptin) | IPAY 2026 (eff. Jan 1 2026) | $527 | $113 | 79% |
| Jardiance (empagliflozin) | IPAY 2026 (eff. Jan 1 2026) | $573 | $197 | 66% |
| Farxiga (dapagliflozin) | IPAY 2026 (eff. Jan 1 2026) | $556 | $178 | 68% |
| Semaglutide (Ozempic/Rybelsus/Wegovy) | IPAY 2027 (eff. Jan 1 2027) | ~$959 | $274 | 71% |
Sources: CMS Medicare Drug Price Negotiation Program, IPAY 2026 and IPAY 2027 selected-drug lists and negotiated price announcements; published manufacturer WAC pricing; ICER Institute for Clinical and Economic Review, diabetes treatment assessment, 2019. Janumet and Tradjenta are confirmed IPAY 2027 additions; their negotiated MFPs are not yet published and are flagged as a methodology gap for a future update rather than estimated here.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Agent-by-agent MFP vs list comparison for all three IPAY 2026 agents
- The formulary-tier implication of a 66-79% list cut landing on a single effective date
- Gross-to-net waterfall showing where existing commercial rebates now sit relative to the negotiated floor
Delivers
- The IPAY 2027 negotiated cohort and its $274 semaglutide MFP mechanics
- Cross-cycle comparison of IPAY 2026 vs IPAY 2027 negotiated agents
- Analysis of which T2D agents remain un-negotiated and their pricing exposure
Delivers
- ICER's 2019 add-on-to-metformin cost-effectiveness findings for both agents
- Reassessment of that ranking against the $197 and $274 negotiated prices
- Formulary-positioning implications for a plan rebuilding its T2D tier after two negotiation cycles
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why two overlapping IRA negotiation cycles, not a single cut, is the pricing fact a T2D formulary strategy must be built around
- Pressure-tested against the IPAY 2026 and IPAY 2027 negotiated lists before the rest of the model is built out
- Januvia, Jardiance, and Farxiga MFP mechanics and January 1 2026 effective date
- The 66-79% discount range and its formulary-tier implications
- Semaglutide franchise MFP at $274, plus Janumet and Tradjenta newly added
- How the negotiated cohort roughly doubles in class scope from 2026 to 2027
- Which T2D agents remain outside both negotiation cycles
- Pricing-parity gap this creates against the negotiated cohort
- 2019 add-on-to-metformin cost-effectiveness findings
- Reassessing the ranking against both agents' negotiated MFPs
- Gross-to-net build from WAC to net for each negotiated agent
- Where existing commercial rebates land relative to the negotiated floor
- Conservative, base, and aggressive formulary-repositioning scenarios
- Sensitivity ranking of negotiation-cycle timing and un-negotiated agent list-price movement
- The open pricing questions your team must close before a T2D formulary position is locked
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model tracks negotiated price by cycle, since IRA negotiation rolls out class by class over multiple years and a single-cycle snapshot understates how much of the formulary is negotiated by the time a plan year takes effect.
Type 2 diabetes US pricing sources: CMS Medicare Drug Price Negotiation Program IPAY 2026 and IPAY 2027 announcements, published manufacturer WAC pricing, and the ICER diabetes treatment value assessment, 2019.
- Januvia, Jardiance, and Farxiga IPAY 2026 negotiated prices and discount percentages verified against the CMS IPAY 2026 selected-drug list and negotiated price announcement
- Semaglutide's IPAY 2027 $274 MFP and 71% discount, plus Janumet and Tradjenta's addition to the same cycle, verified against the CMS IPAY 2027 selected-drug list
- ICER's 2019 oral semaglutide vs empagliflozin cost-effectiveness finding verified against ICER's published 2019 diabetes treatment assessment
- Janumet and Tradjenta's addition to the IPAY 2027 negotiated list is confirmed; their negotiated MFP figures are not yet published and are flagged as a known gap rather than estimated
Frequently asked questions
Commission this model
AXLRx delivers type 2 diabetes pricing strategy models built for market access and pricing teams navigating two overlapping IRA negotiation cycles. Custom model in 72 hours.
Specify your target payer channel, plan mix, and comparator agents.
AXLRx analyst confirms negotiation-cycle scope and formulary comparator set before building.
Research-verified pricing model in 72 hours with optional analyst readout.